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Non-alcoholic fatty liver disease (NAFLD) and its more severe form non-alcoholic
steatohepatitis (NASH) are a major public health concern with high and increasing global
prevalence, and a significant disease burden owing to its progression to more severe
forms of liver disease and the associated risk of cardiovascular disease. Treatment
options, however, remain scarce, and a better understanding of the pathological and
physiological processes involved could enable the development of new therapeutic
strategies. One process implicated in the pathology of NAFLD and NASH is cellular
oxygen sensing, coordinated largely by the hypoxia-inducible factor (HIF) family of
transcription factors. Activation of HIFs has been demonstrated in patients and mouse
models of NAFLD and NASH and studies of activation and inhibition of HIFs using
pharmacological and genetic tools point toward important roles for these transcription
factors in modulating central aspects of the disease. HIFs appear to act in several cell
types in the liver to worsen steatosis, inflammation, and fibrosis, but may nevertheless
improve insulin sensitivity. Moreover, in liver and other tissues, HIF activation alters
mitochondrial respiratory function and metabolism, having an impact on energetic and
redox homeostasis. This article aims to provide an overview of current understanding of
the roles of HIFs in NAFLD, highlighting areas where further research is needed.
Keywords: non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hypoxia-inducible
factor (HIF), chronic intermittent hypoxia, obstructive sleep apnea, fibrosis, metabolism, inflammation
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a progressive, widespread form of chronic liver
disease with a large global burden. Worldwide, around 25% of the population have NAFLD
and its prevalence is increasing (1). NAFLD initially presents as relatively benign fatty liver
but worsens with time, leading to fibrosis and the inflammatory, more severe non-alcoholic
steatohepatitis (NASH). Eventually, even cirrhosis or hepatocellular carcinoma can occur (2). It
is also an important independent risk factor for cardiovascular disease (1). Despite this, specific
treatment options for NAFLD are lacking. In order to develop such specific treatments, a better
understanding of disease mechanisms and the (patho-)physiological signalling systems involved in
NAFLD progression are needed.
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The hypoxia-signalling system has been implicated in the
pathogenesis of NAFLD (3). Central to cellular oxygen-sensing
is the hypoxia-inducible factor (HIF) family of transcription
factors which regulate the expression of genes underpinning the
cellular and systemic response to hypoxia. HIFs are heterodimers,
made up of an alpha subunit (of which three are currently
known: HIF1α, HIF2α, and HIF3α), and a beta subunit (HIF1β).
Current understanding of the regulation and function of HIF1α
and HIF2α, is much greater than that of HIF3α, which remains
under-investigated (4). The 2019 Nobel Prize in Physiology
or Medicine was awarded to William Kaelin Jr., Peter J.
Ratcliffe, and Gregg L. Semenza for their work in revealing
how HIFs sense oxygen levels and coordinate the cellular
response to hypoxia. The sensing mechanism, which has been
reviewed elsewhere (5), involves targeted destruction of HIFα
subunits in the presence of oxygen (Figure 1). Under normoxic
conditions, HIF-prolyl hydroxylase domain proteins (PHD1-
3) hydroxylate proline residues in cytoplasmic HIFα subunits
in an oxygen-dependent manner. This allows recognition by
the E3 ubiquitin ligase von-Hippel Lindau protein (VHL),
leading to ubiquitination of HIFα and subsequent proteasomal
degradation. PHD-mediated hydroxylation does not occur in
hypoxia, allowing HIFα stabilisation, translocation to the nucleus
and dimerization with HIF1β. Activated HIFs bind to hypoxia
response elements in the promoters of target genes, leading to
the transcription of genes required for adaptation to hypoxia,
such as Vegfa, encoding vascular endothelial growth factor, and
genes encodingmany glycolytic enzymes (6). Owing to their roles
in the regulation of diverse processes such as metabolism and
angiogenesis, there is great potential for the involvement of HIFs
in multiple key aspects of NAFLD, and accumulation of HIFs has
been demonstrated to occur in the livers of patients with NAFLD
(3). This makes HIF signalling a promising therapeutic target for
this disease, especially since pharmacological modulators of the
HIF pathway already exist (7–9).
Potential Mechanisms of HIF Activation in
NAFLD
The canonical driver of HIF activation is tissue hypoxia. Hypoxia
in the liver has been shown to occur in mice fed a high fat
diet (HFD) for 8 weeks, though it remains unclear how this
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palmitoyltransferase 1; ECM, Extracellular matrix; Epas1, Endothelial PAS domain
containing protein (gene); FAO, Fatty acid oxidation; Fas, Fatty acid synthase;
HFD, High fat diet; HIF, Hypoxia-inducible factor; HRGP, Histidine rich
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NAFLD, Non-alcoholic fatty liver disease; NASH, Non-alcoholic steatohepatitis;
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local hypoxia develops (10). The liver displays a steep oxygen
gradient, with higher partial pressures of oxygen in the periportal
regions, but lower oxygenation in perivenous regions (11). In
NAFLD, this gradient could become dysregulated, leading to
hepatic hypoxia, and this has been observed using pimonidazole
staining inmice fed aHFD (12). Pimonidazole is a small molecule
that reacts with thiol groups in proteins and peptides specifically
under hypoxic conditions allowing for the detection of hypoxia
using immunohistochemical techniques (13). Dysregulation of
the oxygen gradient in the liver could result from increased size of
hepatocytes (which increases the diffusion distance for oxygen),
e.g., due to steatosis, or from increased oxygen consumption,
which may occur in early stages of NAFLD development as
appears to be the case in HFD fed rats (14, 15). This increase in
oxygen consumption may be a result of increased fat oxidation to
avoid lipid accumulation in a state of high fat intake. In addition
to hypoxia, HIF stabilisation also occurs in response to reactive
oxygen species (ROS) production (16), which is commonly seen
in animals fed a HFD (17), and can be caused by cholesterol
accumulation (18). ROS production could also result from
reduced levels of the sirtuin SIRT4, which have been observed
in patients with NAFLD (19). HIF activation can also result
from succinate accumulation (20). SIRT1 has also been shown
to be an important component of HIF activation (21). However,
it should be noted that SIRT1 is generally downregulated in
patients with NAFLD (22), and it is therefore unclear whether
this mechanism is involved in regulation of HIFs in this context.
While localised hypoxia has been demonstrated in steatotic
mouse livers (10), it remains unclear whether this is driven
by increased diffusion distance, increased oxygen consumption,
or a combination of both. Further, other mechanisms of HIF
activation, such as ROS production and importantly, chronic
intermittent hypoxia (CIH), remain under-investigated in this
context. CIH occurs in humans with obstructive sleep apnoea
(OSA), which causes nocturnal bouts of low blood oxygen
caused by breathing difficulties (23). It is common in patients
with obesity (24), and has been linked to NAFLD severity
(25), but it remains unclear to what extent it is required for
HIF activation in patients with NAFLD, and whether HIF
mediated pathophysiological mechanisms differ between patients
of NAFLD with and those without OSA. It should be noted that
while rodents do not spontaneously develop OSA (meaning CIH
does not occur in rodent models of NAFLD), HIF accumulation
has been demonstrated in the livers of rodent models of NAFLD.
This supports the view that CIH is not necessarily a requirement
for HIF activation in NAFLD. The uncertainty around the
mechanism driving HIF activation in NAFLD is of note, as
mechanistic into this very common disease remains lacking (26),
making it crucial to address such gaps in our understanding of
the pathology of NAFLD.
Metabolic Roles of HIFs in NAFLD
Regulation of cellular metabolism is a major canonical function
of HIFs. In order to maintain energy charge in hypoxia,
HIFs increase the expression of genes encoding glycolytic
enzymes such as lactate dehydrogenase (27), while repressing
the expression of genes involved in oxidative metabolism,
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FIGURE 1 | Pathway of HIF activation in hypoxia. Adapted from Lee et al. (7). Under normoxic conditions, PHD enzymes hydroxylate proline residues in the HIFα
subunit, in an oxygen-dependent manner. The hydroxylated residues are bound by VHL, which ubiquitinates HIFα allowing recognition and destruction of HIFα by the
proteasome. Under hypoxic conditions, hydroxylation cannot occur and HIFα can instead translocate to the nucleus, bind HIFβ and other cofactors to activate
transcription of target genes. HIF accumulation can also result from PHD inhibition by succinate or ROS, or by increased transcription and translation due to a ROS
induced, ERK and PI3K mediated pathway. ERK, extracellular-signal related kinase; HIF, hypoxia-inducible factor; PHD, prolyl hydroxylase domain proteins; PI3K,
phosphoinositide 3-kinase; VHL, Von Hippel Lindau protein.
particularly fatty acid oxidation (FAO) (28). This serves to
decrease oxygen requirements for ATP production, and protects
against cellular damage in short-term hypoxia. However, chronic
activation of HIFs in patients and models of fatty liver disease
(3) may inhibit FAO to such an extent that it leads to or
worsens hepatic lipid accumulation. HIF activation also appears
to worsen steatosis by increasing the expression of genes required
for lipogenesis, and the uptake and storage of lipids (9). Under
normal circumstances, this may be an adaptive response to acute
hypoxia, acting to store energy sources that cannot be utilised due
to the general limitation on oxidative metabolism, and to package
potentially toxic fatty acids as less harmful triglycerides. Overall,
however, the resulting lipid accumulation appears to represent a
harmful role for HIFs in steatotic liver diseases, such as NAFLD.
It may also explain part of the association between severe OSA
severity and incidence of NAFLD (29). Evidence of an insulin-
sensitising role of HIFs in metabolic disease (30) complicates the
overall effect of HIF activation in fatty liver disease, which is
typically associated with insulin resistance (31).
Considerable evidence points toward HIF-mediated
downregulation of FAO in hepatic steatosis. In particular,
HIF2α activation, which occurs in the livers of patients with
NAFLD as well as in mouse models (3), appears to worsen
lipid accumulation (see Figure 2). Early studies in Vhl-deficient
mice, showed that HIF2α, but not HIF1α, is responsible for
the suppression of FAO in these mice (32–34). Vhl-deficient
mice had lower expression of peroxisome proliferator-activated
receptor α (PPARα)-target genes, such as carnitine-palmitoyl
transferase 1 (Cpt1) and acyl CoA oxidase (Acox), lowering
fatty acid-supported oxidative phosphorylation (33). PPARs
are a family of transcription factors activated by unsaturated
fatty acids, amongst other ligands. They play a key role in the
control of fatty acid metabolism, and PPARα in particular is a
major regulator of FAO in the liver (35). The reduced expression
of PPARα target genes in Vhl-deficient mice was prevented by
deletion of Epas1 (endothelial PAS domain containing protein 1,
the gene encoding HIF2α) but not Hif1a deletion (32). Similarly,
primary hepatocytes from Vhl-deficient mice showed increased
lipid accumulation alongside low expression of PPARα target
genes (36). Indeed, HIF2α binds the PPARα promoter to repress
its expression in HEK293 cells (28).Hif2a deletion or knockdown
using siRNA prevents hypoxia-associated lipid accumulation in
the human hepatocellular carcinoma HepG2 cell line (37, 38).
Hypoxia appears to cause lipid accumulation in these cells by
stabilising HIF2α, thereby lowering expression of FAO genes
such as Cpt1 and PPARγ coactivator α (Pgc1α) (38). Expression
of these genes was normalised by Hif2a deletion, leading to
decreased lipid accumulation. These studies demonstrate a
potential role for HIF2α activation in decreasing the capacity for
FAO in the liver, which could worsen steatosis in the context of
NAFLD, when dietary fat intake is typically high.
While it is clear that HIF, and in particular HIF2α, activation
can limit FAO in the liver to worsen steatosis, the studies
outlined above did not investigate whether this occurs in NAFLD.
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FIGURE 2 | Putatively beneficial and harmful effects of HIF2 activation in hepatocytes in NAFLD and NASH. HIF2 activation leads to lower expression of FAO genes,
including Ppara, which encodes PPARα. This decreases FAO, leading to increased lipid accumulation. Higher levels of fibrogenic mediators such as LOX and
potentially PAI-1, which are involved in ECM deposition, also occur as a result of HIF2 activation. Increased production of HSC activators may also occur but this has
not yet been demonstrated in NAFLD/NASH. HIF2 mediated upregulation of the pro-inflammatory cytokine HRGP worsens inflammation. Interplay between HIF2 and
NF-κB appears likely, but details of this interaction are unknown. Finally, increased transcription of the insulin signalling component Irs2 appears to improve insulin
signalling to prevent insulin resistance. ECM, extracellular matrix; FAO, fatty acid oxidation; HIF, hypoxia-inducible factor; Hrgp, histidine rich glycoprotein; HSC,
hepatic stellate cell; Irs2, insulin receptor substrate 2; Lox, lysyl oxidase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; Ppara, peroxisome
proliferator-activated receptor α; Fas, fatty acid synthase; CD36, cluster of differentiation 36; Pdgfb, platelet derived growth factor b.
Studies in in vitro systems and animal models of NAFLD
suggest that this is indeed the case. Mice exposed to a HFD
to induce hepatosteatosis showed decreased lipid accumulation
when treated with a HIF2α antagonist (9), though FAO was
not investigated in this study. In L02 human hepatocytes
treated with fatty acids to model NAFLD in vitro, hypoxia
worsened lipid accumulation, and this was associated with
increased HIF2α levels, decreased expression of Ppara and
transcriptional targets of PPARα such as Cpt1a and Acox, and
lower oxidation of oleate (39). Silencing of Hif2a or treatment
with a PPARα agonist, normalised expression of FAO genes
and oleate oxidation, thereby lowering lipid accumulation, while
treatment with a PPARα inhibitor prevented the beneficial effect
of HIF2α-silencing. The authors also found that exposure of
HFD fed mice to CIH, which models OSA, (see Table 2 for an
overview of hypoxia animal and cell culture models) increased
lipid accumulation in the liver and decreased the expression of
FAO genes including Ppara, Cpt1a, and Acox2. PPARα agonist
treatment reversed the effects of hypoxia on steatosis. Chen et al.
(39) did not investigate whether HIF2α activation played a role in
lipid accumulation in the absence of a hypoxic stimulus, although
other studies have demonstrated that HIF2α accumulation occurs
in animalmodels of NAFLDwithout added hypoxia (40). Hepatic
Hif1α deletion in a mouse model of NAFLD (mice fed a
choline deficient diet), however, led to lower Lipin1 mediated
PPARα/PGC1α pathway activation, which worsened steatosis
relative to wild type mice (41), suggesting HIF1α is required to
maintain FAO in NAFLD. Further work is required to determine
whether HIF2α activation in NAFLD leads to lower FAO in
animal models and human patients, especially in the absence of
imposed hypoxia, though current evidence suggests that HIF2α
activation in NAFLD contributes to hepatic steatosis, and that
HIF2α activation can limit fatty acid oxidation, whereas HIF1α
appears to be required for FAO in NAFLD.
Increased lipogenesis is an important feature of NAFLD in
human patients (42–44). Again, studies support a potential HIF-
mediated upregulation of this process in the context of NAFLD,
although the current evidence for this role of HIF is conflicting.
Studies of animal models of NAFLD suggest that HIF2α
activation in this disease context may drive increased lipogenesis,
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thus worsening lipid accumulation in the liver (see Figure 2).
Treatment with the HIF2α specific antagonist PT2399 lowered
hepatic steatosis in HFD fed mice (9), and this was associated
with decreased expression of lipogenic genes in the liver. In L02
human hepatocytes treated with fatty acids, hypoxia (1% oxygen
in hypoxic cell culture incubators) increased the expression of
lipogenic genes such as Fas and stearoyl CoA dehydrogenase
1 (Scd1), and this was normalised by HIF2α silencing (39).
Similarly, mice fed aHFD and subjected to CIH showed increased
expression of Fas and Scd1 relative to HFD fed mice not exposed
to CIH (39). Conversely, oxygen therapy, which preventedHIF2α
accumulation, lowered hepatic steatosis in HFD fed mice, and
lipid accumulation in primary hepatocytes exposed to fatty acids.
This also normalised expression of lipogenic genes in both in vivo
and in vitro models of hepatosteatosis (40). Thus, it appears that
HIF2α-activation, resulting from hypoxia, worsens diet induced
steatosis by activating lipogenic gene expression. However, it
should be noted that genetic HIF2α activation via Vhl disruption
has been associated with decreased expression of lipogenic genes
such as fatty acid synthase (Fas) (32), or, in other studies
using the same mechanism, with only a temporary increase
in lipogenic gene expression 3 days after the Vhl disruption
(34). These conflicting results may be due to the differing
mechanisms of HIF2α activation. In addition to increasing
lipogenesis, HIF2α upregulation in NAFLD appears to increase
lipid uptake by upregulating the fatty acid transporter Cluster
of Differentiation 36 (CD36) (45). CD36 expression correlates
with HIF2α levels in patients with NAFLD, and hypoxia induces
CD36 expression in mouse AML12 hepatocytes exposed to
hypoxia (45). Therefore, there is evidence that HIF2α activation
(via genetic manipulation or hypoxia) can cause steatosis via
inhibition of FAO and upregulation of lipid uptake, that liver
hypoxia and HIF2α activation occur in NAFLD, and that HIF2α
upregulates lipogenesis in diet-induced steatosis, which worsens
lipid accumulation and can be prevented by treatment with
HIF2α antagonists. However, whether HIF2α also impairs FAO
in NAFLD remains unclear.
OSA also induces metabolic changes that may be mediated
by HIF signalling. Levels of the CD36 are higher in the livers of
patients with OSA than in those of healthy controls, and correlate
with severity of OSA (46). CIH, which mimics OSA, induces the
expression of lipogenic genes, such as Scd1, and CD36 in wild
type (46) and ob/ob mice (47). Moreover, CIH increased HIF2α,
but not HIF1α levels in HFD fed mice, while decreasing the
expression of FAO genes such Cpt1a (39). Thus, it appears likely
that HIF signalling decreases FAO and increases lipid uptake and
lipogenesis to worsen steatosis in the context of OSA and CIH,
though the link between CIH/OSA and HIF signalling has not
yet been established.
The role that HIF activation plays in the context of obesity
associated disease is complicated by evidence of a link between
HIF and insulin signalling. Both HIF1α and HIF2α activation
have been shown to alter insulin sensitivity and glucose handling,
most likely in a beneficial manner (see Figures 2, 3). Owing
to its role in upregulating glycolytic enzymes, it seems likely
that HIF1α could improve glucose handling in obesity and
diabetes. Indeed, HIF1α was upregulated in the livers of mice fed
a high-fat, high-sucrose diet (30). Hepatocyte-specific deletion
of Hif1a was associated with worsened glucose handling and
insulin sensitivity. This was associated with lower levels of
hepatic glucokinase (30). Treatment of HFD fed mice with
HIF1α antisense oligonucleotides, however, decreased blood
glucose and insulin levels (48). Unlike the hepatocyte-specific
deletion employed by Ochiai et al. (30), this not only interfered
with Hif1a in the liver, but also in adipose tissue, which may
explain the opposing results. Shin et al. (48) found increased
energy expenditure and lower body weight in Hif1a antisense
oligonucleotide-treated animals. Hif1a antisense oligonucleotide
treatment was also associated with lower liver steatosis, increased
hepatic Ppara expression, and decreased expression of the
lipogenic genes Scd1 and acetyl-CoA carboxylase (48), though
again it is unclear whether this was due to Hif1a interference in
the liver or secondary to effects in other tissues. Overall, it appears
that HIF1α activation can have opposing effects on insulin
sensitivity, which may be tissue specific. This could explain why
OSA severity is associated with worsened insulin resistance in
patients with NAFLD (29) while liver-specific deletion of Hif1a
worsens HFD induced glucose intolerance in mice (30).
HIF2α also appears to be involved in hepatic insulin signalling,
via direct modulation of components of the insulin-signalling
pathway. Liver-specific HIF2α (but not HIF1α) activation led to
improved insulin tolerance and glucose handling (49). HIF2α
directly upregulates the insulin-signalling pathway component
insulin receptor substrate 2 (IRS2) by binding to HREs in
its promoter and Irs2 was required for the HIF2α-mediated
effect on insulin sensitivity. Similarly, hepatic deletion of Phd3,
which specifically upregulated HIF2α, was associated with
increased Irs2 transcription, improving insulin sensitivity (50).
Again, this beneficial effect required both Hif2a and Irs2. Phd3
deletion was associated with lower expression of gluconeogenic
[e.g., phosphoenolpyruvate carboxykinase (Pepck)] and lipogenic
(e.g., Fas) genes. Interestingly, unlike other models of liver
specific HIF2α activation, Phd3 deletion was not associated
with worsened steatosis. The authors observed that deletion of
Phd1-3, which increased HIF2α stabilisation still further, did
worsen steatosis, suggesting that lower level HIF2α activation
may be predominantly beneficial via improved insulin sensitivity,
while higher levels of stabilisation, as occurs with Phd1-3
and Vhl deletion (and potentially in long-term NAFLD) has
a detrimental effect due to inhibition of FAO, leading to
worsened steatosis.
Overall, significant evidence points toward a steatosis-
promoting role for chronic HIF2α activation in liver,
likely occurring via inhibition of FAO and upregulation of
lipogenesis, though studies investigating the effect of Hif2a
deletion in NAFLD on FAO are needed to confirm this.
Meanwhile, low levels of HIF2α activation in metabolic diseases
appear to have a beneficial effect on insulin sensitivity and
glucose handling. Whether HIF1α activation is protective
or harmful in the context of metabolic disease and hepatic
steatosis remains less clear. There are conflicting results
which may be the result of opposing roles in different
cell types and tissues, although in hepatocytes specifically,
HIF1α activation in obesity appears to improve insulin
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FIGURE 3 | Putatively beneficial and harmful effects of HIF1 activation in NAFLD and NASH. (A) In hepatocytes, HIF1 activation leads to increased expression of
fibrogenic genes, including genes responsible for HSC activation (e.g., Pdgfb), ECM deposition (e.g., Lox), and pathological angiogenesis (Vegfa). Pathological
angiogenesis has only been investigated in fibrosis models, not NAFLD models. HIF activation also increases expression of glycolytic genes such as glucokinase and
glucose transporters, which increases glucose consumption and improves glucose handling. This can help prevent insulin resistance. (B) In macrophages, including
resident macrophages in the liver, Kupffer cells, HIF1 activation increases expression of pro-inflammatory cytokines such as Il1b, leading to inflammation, and of
fibrogenic genes, such as the HSC activator Pdgfb, leading to fibrosis. HIF1 also appears to activate NF-κB, a key regulator of fibrosis and inflammation. (C) In HSCs,
which will be activated at increased levels due to signals from other cells resulting from HIF1 activation, HIF1 activation is also required for transcription of fibrogenic
genes, such as Col1, encoding Type 1 Collagen. For many of these effects of HIF1 activation, the precise mechanisms are not yet clear and not all genes mentioned
are necessarily under direct HIF1 control. Col1, Type 1 Collagen; Gck, glucokinase; ECM, extracellular matrix; HIF, hypoxia-inducible factor; HSC, hepatic stellate cell;
Il1b, interleukin 1b; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; Pdgfb, platelet derived growth factor b; Vegfa, vascular endothelial growth
factor A.
sensitivity and may be required to maintain FAO and prevent
increased lipogenesis.
HIFs and Fibrosis in NAFLD and NASH
Fibrosis is a key component of NAFLD in its most severe
forms (51) and can occur both in patients of non-inflammatory
non-alcoholic fatty liver and of inflammatory NASH (52). It is
associated with worse outcomes and higher mortality rates in
patients with NAFLD (53, 54). HIF-signalling likely contributes
to fibrosis in NAFLD as shown by studies of fibrosis in general,
and of fibrosis in NAFLD in particular. Liver hypoxia has been
demonstrated in animal models of fibrotic and cirrhotic liver
disease (see Table 1 for an overview of fibrosis, cirrhosis, and
NAFLD models), including in diethylnitrosamine cirrhosis (72),
CCl4 induced fibrosis (73), bile duct ligation (BDL) (74), and
high dietary trans-fat induced NAFLD (56), and increased levels
of HIF1α have been found in mouse models (75) and patients
with fibrotic liver disease (76). Deletion of Hif1a protects against
liver fibrosis in mouse models of both fibrotic liver disease,
such as mice subjected to BDL (74), and models of NAFLD
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TABLE 1 | Rodent models for the study of NAFLD.
Disease Model Aspects of NAFLD/NASH captured References
NAFLD High fat diet with varying fat content Obesity, hepatic steatosis, often insulin resistance, sometimes liver
fibrosis, inflammation
(17, 30)
ob/ob mouse Obesity, steatosis, mild fibrosis (55)
db/db mouse Obesity, insulin resistance, steatosis, mild fibrosis (55)
High trans-fat diet Obesity, with steatosis, fibrosis and some inflammation (56)
NASH Gubra-Amylin-NASH diet (high fat, high
fructose, high cholesterol)
Obesity, severe steatosis, moderate inflammation, moderate
fibrosis
(57)
ob/ob mouse with high calorie feeding Obesity, steatosis, moderate fibrosis, inflammation, moderate
fibrosis
(55)
db/db mouse with high calorie feeding Obesity, insulin resistance (55)
Choline-deficient, L-amino acid-defined diet No obesity, steatohepatitis and fibrosis (3)




Bile duct ligation Liver fibrosis (59)
Repeated CCl4 injection Liver fibrosis (60–62)
Cirrhotic liver
disease
Diethylnitrosamine injection/feeding Severe liver injury and cirrhosis, can induce hepatocarcinoma (63)
TABLE 2 | Relevant in vitro and in vivo models of chronic and chronic intermittent hypoxia.
System Model Details of model References
in vitro Cells cultured in hypoxic chambers Constant hypoxia achieved using high levels of nitrogen. Range
oxygen concentrations can be used, 1% most common. Wide
range of timeframes.
(64, 65)
Cells treated with cobalt chloride Model of HIF activation similar to constant hypoxia. Cellular
response sometimes differs from true hypoxia.
(65, 66)
Cells cultured in hypoxic chambers with cycling
oxygen levels
Models CIH in vitro. Wide range of oxygen levels at nadir and cycle
patterns in use.
(65)
in vivo Rodents in hypoxic chambers Constant hypoxia achieved using high levels of nitrogen. Range of
oxygen concentrations in use.
(67, 68)
Rodents in hypoxic chambers with cycling
oxygen levels
Chronic intermittent hypoxia to model OSA. Oxygen cycles often
applied only during sleeping hours of rodents. Wide range of
oxygen levels at nadir and cycle patterns in use.
(39, 69)
Rodents injected with sodium nitrite Chronic intermittent hypoxemia through methemoglobinemia. (70, 71)
(56, 77). Similarly, hepatocyte-specific deletion of Vhl, which
increases both HIF1α and HIF2α signalling led to fibrosis which
was normalised by Hif2a (but not Hif1a) deletion (34), and
hepatocyte-specific deletion of Hif2a protects against fibrosis
in mouse models of NAFLD (3). It therefore appears likely
that HIF-signalling contributes to liver fibrosis in NAFLD. HIF-
signalling may be involved in fibrosis via several mechanisms,
including regulation of the expression of fibrogenic mediators
in hepatocytes, Kupffer cells (resident macrophages in the
liver) and hepatic stellate cells (HSCs) (see Figure 3), and by
contributing to aberrant angiogenesis, a process that occurs in
parallel with fibrosis and appears to be mechanistically linked to
it (78).
HIF regulated expression of fibrogenic mediators in
hepatocytes has been demonstrated in several relevant in
vitro and in vivo models. Isolated mouse hepatocytes exposed
to hypoxia show increased expression of plasminogen activator-
inhibitor 1 (PAI-1), and this is partially prevented by Hif1a
deletion and completely prevented by Hif1b deletion, suggesting
both HIF1α and HIF2α may be involved (79) (Figures 2, 3).
PAI-1 contributes to fibrosis by inhibiting the activities of
matrix metalloproteinases, leading to excessive collagen and
extracellular matrix (ECM) accumulation (80). Similarly, AML12
mouse hepatocyte cells exposed to hypoxia (81), and HepG2 cells
treated with the HIF stabiliser cobalt chloride and free fatty acids
(66) show increased expression of genes encoding pro-fibrotic
proteins, such as Type 1 Collagen α (COL1A1) and α-smooth
muscle actin (α-SMA). In NAFLD models (Table 1), hepatocyte-
specific deletion of Hif1a protects against collagen deposition
and suppresses collagen crosslinking in the media of isolated
hepatocytes exposed to hypoxia (56). This is likely to be due to
decreased lysyl oxidase (Lox) expression, which requires Hif1a
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in vitro (56). Lox expression has also been shown by chromatin
immunoprecipitation to be under the control of HIF2α (34). In
another study of NAFLD models, hepatocyte-specific deletion
of Hif1a decreased collagen deposition and α smooth muscle
actin staining (77). HepG2 cells treated with palmitic acid also
showed increased HIF1α levels, and increased Type I Collagen
and fibronectin expression, which was prevented by treatment
with Hif1a siRNA (77). Further, hepatocyte-specific deletion
of Hif2a protected against fibrosis in choline deficient, amino
acid defined diet fed mice, a model of lean NAFLD (3). This
was associated with lower levels of Col1 (Collagen I) and Acta2
(αSMA) mRNA. Collectively, these studies highlight that one
role of HIF activation in liver fibrosis is the direct regulation
of fibrogenic genes in hepatocytes and that this likely occurs in
NAFLD. However, hepatocytes are not considered major sources
of ECM deposition in vivo, and so it remains unclear how central
this mechanism is to the pathology of NAFLD.
HSCs are the main source of myofibroblasts and therefore
fibrosis in liver disease. Myofibroblasts form in the injured liver
in response to fibrogenic signals and are themajor source of ECM
deposition in fibrosis. They are not found in the healthy liver
(82). Hypoxia and HIF-signalling appear to play an important
role in the activation of HSCs and in regulating the expression of
fibrogenic mediators in HSCs. Hypoxia increases the expression
of Type I collagen in activated HSCs (72) and HIF-signalling is
required for the expression of collagen synthesis genes in isolated
HSCs (83) and the production of HSC activators (including
platelet derived growth factor (PDGF)-B) in livers in BDL (74),
which suggests hypoxia signalling in hepatocytes may play an
important role in activating HSCs. Further evidence for this
comes from in vitro studies; HIF signalling is required for the
upregulation of HSC activators in isolated mouse hepatocytes
exposed to hypoxia (79), and the conditioned medium of AML12
cells exposed to hypoxia induces α-SMA expression in HSC-T6
cells (81). Similarly, extracellular vesicles isolated from HepG2
cells treated with fatty acids and cobalt chloride to stabilise
HIFs induced the expression of fibrotic genes such as Collagen-
1 and α-SMA in the human HSC LX2 cell line (66). HSCs
are also activated by Kupffer cells and isolated Kupffer cells
exposed to hypoxia show increased PDGF-B expression (84).
This is normalised by Hif1b deletion (84) and myeloid specific
deletion of Hif1a or b protects against fibrosis in BDL (85).
Overall, evidence suggests that HIF-signalling is involved in HSC
activation by acting directly in HSCs to increase expression of
fibrogenic mediators, as well as by increasing the expression of
signalling factors that activate HSCs in hepatocytes and Kupffer
cells, though this has not been investigated in the context of
NAFLD in vivo and the relative importance of HIF1 and HIF2
remains unclear.
A further important mechanism linking fibrosis and HIF-
signalling is pathological angiogenesis; a common feature of
fibrosis and cirrhosis that appears to be closely linked to fibrosis
(78). Physiologically, angiogenesis is an important feature of
the adaptive response to hypoxia, and is especially vital in
liver regeneration after injury, to enable blood supply to re-
growing liver regions. It is largely driven by HIF1α-mediated
expression of VEGF and treatment with the PHD inhibitor
DMOG increases the speed of liver regeneration in rats after
portal vein ligation and parenchymal transection, and portal
vein ligation alone (86). In pathological or aberrant angiogenesis
however, immature neovessels form, which are incapable of
resolving localised hypoxia in liver disease, and may lead to
chronic HIF activation. Aberrant angiogenesis is likely mediated
by increased VEGF expression in fibrosis due to activated
HIF signalling (72). Anti-angiogenic treatment with VEGF
neutralising antibodies or the VEGF Receptor 2 inhibitor
sorafenib can prevent fibrosis in BDL models of liver fibrosis
(87, 88), althoughVEGFmay also play a role in fibrosis resolution
(88). VEGF expression is increased in hypoxic hepatocytes in
a HIF1α-dependent manner (79) and in hypoxic Kupffer cells
in a HIF1β-dependent manner (84). VEGF-signalling is highly
active in HSCs from areas of active fibrogenesis in patients
and animal models, and VEGF stimulates HSC chemotaxis
(89). T6-HSCs exposed to hypoxia have reduced levels of VHL,
resulting in increased HIF1α and VEGF expression, which is
normalised by cyclooxygenase 2 inhibition (90). Thus, chronic
HIF-activation may contribute to fibrosis by upregulating VEGF,
which contributes to HSC activation and leads to aberrant
angiogenesis. However, this has only been investigated in models
of fibrotic liver disease, rather than non-alcoholic or metabolic
associated fatty liver disease, and further work is required to
determine whether pathological angiogenesis is also involved in
these conditions.
Hypoxia signalling may also be linked to fibrosis via
interaction with nuclear factor (NF)-κB signalling. NF-κB is
thought to be an important driver of fibrosis and inflammation
in NAFLD (91) and inactivation of NF-κB, in particular in
Kupffer cells, protects against fibrosis in mice injected with
CCl4 (60). NF-κB signalling is also activated in HSCs and
myofibroblasts in the livers of CCl4 and BDL rodent models,
and human patients of fibrotic liver disease (92). There is
considerable evidence of crosstalk between NF-κB and HIF
signalling (93, 94), particularly in immune cells (95). However,
the specific link between HIF and NF-κB signalling in the context
of NAFLD remains less clear. While it has been demonstrated
that both HIF2α and NF-κB accumulate in the livers of
patients with NASH and mice exposed to hypoxia (96), it is
unclear whether their respective signalling pathways interact and
whether modulation of either can affect the other, and thereby
improve fibrosis.
A link between OSA and liver fibrosis in NAFLD also appears
likely. In patients with OSA and obesity, more severe OSA was
associated with worsened fibrosis (29), and circulating levels of
LOX (which is regulated by HIFs) are higher in patients with
obesity and more severe OSA (64). In mice fed a high trans-fat
diet and exposed to CIH (97), and in rats fed a HFD to induce
NASH and injected with sodium nitrite to mimic CIH (70)
fibrosis worsened. It is not clear what mechanisms contributed
to this. In the NASH rat model (70), sodium nitrite injection was
associated with increased HIF1α, VEGFA and VEGF receptor
2 levels. Silencing of HIF1α, however, normalised VEGFA
and VEGF receptor 2 levels and improved fibrosis, suggesting
pathological angiogenesis driven by HIF1α signalling may play
a role. VEGF receptor neutralising antibodies attenuated the
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development of fibrosis in CCl4 induced fibrosis, and VEGF
stimulated HSC proliferation in vitro (98), further supporting
a role for pathological angiogenesis. However, the link between
CIH and fibrosis may not always be HIF1α mediated, as, while
HIF1α deletion improved liver fibrosis and inflammation in
trans-fat diet fed mice with or without CIH, it did so without
significant interaction with CIH effects (97). Further research
is needed to understand the mechanisms involved in the link
between CIH/OSA and liver fibrosis.
HIFs and Inflammation in NAFLD and NASH
Hypoxia is a common feature of chronically-inflamed tissue, and,
as highlighted by a number of recent reviews (99–102), HIFs play
important roles in inflammation and immunity, including via
the activation of macrophages and certain types of T cells, and
regulation of inflammatory cytokine expression, partly mediated
via crosstalk with NF-κB signalling (103). Current evidence
suggests that both HIF1α and HIF2α play a harmful role in
NASH (Figures 2, 3), a more severe form of NAFLD with
marked liver inflammation (104). This involves hepatocyte-
specific and immune cell-specific roles of HIFs. Hepatocyte-
specific normoxic activation of HIF1α and HIF2α via deletion
of Vhl worsens lipid accumulation, fibrosis and inflammation,
with global microarray expression analysis showing increased
expression of proinflammatory cytokines (34). This pathological
phenotype was averted by concomitant deletion of Hif2a, but
not Hif1a, suggesting a greater importance for HIF2α in driving
steatohepatitis in hepatocytes. Similarly, in patients with NAFLD,
hepatic levels of HIF2α and HIF1α are increased in early, non-
inflamed stages of NAFLD, but only HIF2α levels are further
increased in the livers of patients with NASH vs. patients with
non-inflamed NAFLD (40), though studies in animal models do
suggest a possible role for HIF1α as well (97).
In NASH, treatment studies and genetic interference with
the HIF pathway point toward HIF activation contributing to
inflammation. Treatment with the cardiac glycoside digoxin
suppressed HIF1α pathway activation and decreased neutrophil
and monocyte infiltration, as well as liver damage, in a
mouse model of NASH (105). Further, HIF1α was increased
in macrophages from patients and a mouse model of NASH
(106). Myeloid specific HIF1α stabilisation worsened steatosis
and inflammation, with increased macrophage infiltration in
the liver, higher expression of the proinflammatory cytokines
macrophage chemoattractant protein 1 (MCP1) and interleukin
(IL)-1b in liver macrophages, and higher hepatic levels
of Mcp1 and tumour necrosis factor α (Tnfa) mRNA.
Palmitic acid treatment also induced HIF1α in macrophages
in vitro, and silencing of Hif1a suppressed the activation
of NF-κB (106). HIF2α, which is also increased in patients
and mouse models of NASH, appears to influence liver
inflammation via control of hepatocyte production of the
cytokine histidine rich glycoprotein (HRGP) (3). HRGP induces
a proinflammatory M1 phenotype in macrophages, and deletion
protects against NASH in methionine-choline deficient diet
fed mice (107). Choline-deficient, amino acid-defined diet
feeding, another model of NASH, increased levels of HRGP
and other proinflammatory cytokines (including TNFα) in
mouse livers. This was prevented by Hif2a deletion, whilst
overexpression of Hif2α increased HRGP levels in HepG2 cells
(3). It therefore appears that both HIF1α and HIF2α contribute
to inflammation in NASH, and that this involves HIF-mediated
mechanisms in several cell types, especially hepatocytes and
macrophages. How these mechanisms function is not entirely
clear, however.
HIF-signalling may also be involved in the link between OSA
and NAFLD progression generally, and regarding inflammation
in particular. Severity of nocturnal hypoxia in OSA correlates
with NAFLD/NASH severity, including liver inflammation,
independent of other risk factors in patients (25), and subjecting
mice to CIH in order to mimic OSA leads to increased liver
HIF1α, TNFα, and NF-κB (108). OSA induced inflammation
may be mediated in part by changes in the balance between
anti-inflammatory regulatory T cells and pro-inflammatory
Th17 helper T cells (109). In mice fed a HFD, this ratio
was shifted toward the pro-inflammatory Th17 cells, and this
shift was even greater when CIH was superimposed through
injection of sodium nitrite. Interference of HIF1α partially
normalised this shift in the CIH and HFD exposed mice,
and in hypoxic T-cells in vitro. This suggests HIF signalling
in patients with NAFLD/NASH and OSA may induce or
worsen inflammation, though more studies are needed to
confirm this.
OPEN QUESTIONS
The evidence currently available highlights potential mechanisms
by which HIF signalling may be involved in several key aspects
of NAFLD, namely steatosis, inflammation and fibrosis. Further
work is required to confirm many of these mechanisms and
provide a more detailed understanding, and to determine
whether targeting HIF signalling is a viable treatment strategy to
improve these aspects of the pathology. It also remains uncertain
what drives liver hypoxia and HIF activation in NAFLD in the
first place.
While high fat feeding has been shown to induce liver
hypoxia even in a relatively short time frame (10), it has
not yet been determined what processes lead to this. It also
remains unclear whether ROS production plays a role in HIF
induction in NAFLD. Short-term feeding of NAFLD inducing
diets combined with measurement of oxidative metabolism
[e.g., using mitochondrial respirometry (110) or metabolomics,
especially with isotope tracing (111, 112)] in the liver could
elucidate whether development of liver hypoxia is preceded by
increased oxygen consumption. Concomitantly, measurement of
ROS markers [such as thiol (113) or lipid peroxidation (114)]
could show whether ROS production is likely to play a role in
HIF activation, which could be followed up with in vitro studies
using ROS scavengers to investigate whether this prevents HIF
activation in in vitro models of NAFLD. Investigation of SIRT4
in this context could also be valuable as reduced levels of this
sirtuin have been demonstrated in patients with NAFLD (19) and
it has been proposed that this may be a driver of increased ROS
production in this disease.
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It has been demonstrated that HIF2α activation in normoxia
can limit FAO in hepatocytes (32). However, as demonstrated
by the observation that lipogenic gene expression is decreased
in mice with HIF2α activation due to Vhl disruption (32), while
it is increased in NAFLD rodent models (9) [which also show
HIF2α activation (3)], this does not necessarily mean that HIF2α
in NAFLD also reduces FAO. Studies that investigate the function
and expression of enzymes involved in FAO, and of the key
cellular organelle in oxidative metabolism, the mitochondrion,
in NAFLD models (with HIF2α deletion or pharmacological
inhibition) and patients would help elucidate this. More
detailed metabolomic studies in these settings may also provide
further insight into how HIF2α activation affects metabolism
in NAFLD.
In many cases, details of the signalling pathways by which
HIF activation contributes to NAFLD and NASH remain
unclear. This includes the pathways leading to increased
expression of lipogenic, fibrogenic, and pro-inflammatory genes.
Biochemical andmolecular biology techniques such as chromatin
immunoprecipitation and co-immunoprecipitation may provide
targets for further investigation. In vitro studies may prove
useful to probe these targets due to the greater ease of
deletion and overexpression of genes. However, the current
lack of consistent in vitro NAFLD models may make this
more challenging.
Currently, it is unclear to what extent OSA is required
for HIF activation in patients with NAFLD, and whether
HIF activation resulting from OSA differs in its effects on
NAFLD from HIF activation without OSA. This is likely to be
the case due to the hypoxia-reoxygenation cycles inherent to
OSA, which may affect activation of HIFs (e.g., by favouring
HIF1α over HIF2α activation) and other co-activated pathways.
Further investigations into how closely linked HIF activation
and OSA are in patients with NAFLD would be useful, and
studies in animal models of NAFLD exposed to CIH—a way
of mimicking OSA in rodents, which do not develop OSA
spontaneously—could provide insight into whether and how
these pathophysiological mechanisms differ.
The ultimate goal of understanding the involvement of HIF
signalling in NAFLD would be to attempt to treat the disease
by targeting this pathway. Current evidence supports the use of
animal studies to investigate this, and both HIF1α and HIF2α
antagonists have been developed, largely with a view to treating
cancers (8). Early studies, looking for example at the effect of
HIF2α antagonism in HFD induced hepatosteatosis in mice have
shown promising results (9), but studies in more severe models
of NAFLD and NASH do still need be conducted.
Finally, while this review has focussed on the role of HIF
signalling in the liver, some studies point toward roles of
HIFs in other tissues and organs that are likely to impact on
NAFLD and outcomes in NAFLD. For example, HIF activation
in adipocytes (115) and adipose tissue macrophages (116) has
been shown to affect insulin resistance, which is likely to affect
NAFLD development. Further, the close links between gut and
liver are likely to be involved in NAFLD, as shown by the
association between inflammatory bowel disease and NAFLD
(117). HIFs are known to play an important role in inflammation
in the intestine (118) and may be an important part of this
inter-organ link. Indeed, HIF activation in the intestine can
affect NAFLD directly (119). The role of HIFs in other organs
in the broader context of metabolic disease has recently been
reviewed elsewhere (120), and better understanding of this, and
how it may affect interactions between other organs and the
liver is likely to aid in the development of therapeutic strategies
for NAFLD.
CONCLUSION
In conclusion, considerable evidence points toward HIF
activation occurring in NAFLD and NASH, and having
widespread, predominantly harmful effects. Both HIF1α and
HIF2α activation appear to worsen inflammation, though the
mechanisms involved in this require further study. Further,
evidence from studies of fibrosis shows important HIF mediated
mechanisms, including control of profibrotic gene expression
in hepatocytes and HSCs, regulation of HSC activation and
HIF mediated pathological angiogenesis, though only control of
profibrotic gene expression has been demonstrated to occur in
animal models of NAFLD and NASH. Evidence also highlights
a role for HIFs, in particular HIF2α, in driving steatosis.
Studies of HIF activation under normoxic conditions suggest that
HIF2α can inhibit FAO, while studies that interfere with HIF2α
activation in NAFLD via oxygen therapy or antagonism suggest
that HIF2α drives lipogenesis. These mechanisms could explain
the protective effect that Hif2α deletion has against steatosis
in NAFLD. While some beneficial effects of HIF activation
have been noted, such as a potential role in improving insulin
sensitivity, on balance, HIF activation appears to be harmful in
NAFLD, andmay therefore be a useful therapeutic target. Further
research is required to fully elucidate the mechanisms by which
HIF activation contributes to NAFLD and NASH, in particular
the effect on FAO, the signalling pathways involved in regulating
the expression of lipogenic, fibrogenic, and pro-inflammatory
genes, and the link between HIF signalling and OSA in NAFLD
and NASH.
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